MDMA vs Ketamine vs Psilocybin vs EMDR: How to Compare Trauma Treatments

These four treatments are discussed as if they were interchangeable. They are not. One of them involves no drug at all, another can be taken home, and only one has ever had a Phase 3 trial for PTSD. Comparing them properly means holding the differences in mind rather than flattening them into a single question of "which psychedelic works best".

Start with the one that has no drug

EMDR — eye movement desensitisation and reprocessing — is a psychotherapy in which the patient revisits traumatic material while holding a bilateral stimulus, usually the therapist's moving finger. It is an established, guideline-recommended treatment for PTSD, it is widely available, it requires no medical screening beyond the ordinary, and it is not a controlled substance in any country. If you have not tried it, it is the sensible first comparison because it is the one you can probably access this month.

Its limitation is the one every exposure-based therapy shares: it asks you to hold the memory in mind while staying regulated, which is exactly the thing that is hard about PTSD.

Ketamine: fast, and separate from therapy

Ketamine is an anaesthetic at higher doses and a rapid-acting antidepressant at lower ones. In the US, esketamine (Spravato) is an approved nasal treatment for treatment-resistant depression, and racemic ketamine is widely prescribed off-label by mouth or infusion. The relevant difference from MDMA is structural: a ketamine dose can be given as a stand-alone medical procedure, and at-home oral ketamine is now prescribed by some telehealth services.

That convenience is also the trade-off. Ketamine's evidence base is strongest for depression, and repeated use carries genuine risks — bladder inflammation, tolerance, and dependence — that MDMA's clinical-trial exposure of one to three doses does not. For PTSD specifically, ketamine evidence is promising but thinner, and it does not include the therapy hours that MDMA's trials treated as inseparable from the drug.

Psilocybin: the closest analogue, still earlier

Psilocybin-assisted therapy is delivered in the same shape as MDMA-assisted therapy — preparation, a long supervised dosing session, integration — which is why the two are so often discussed together. The evidence is thinner for PTSD and stronger for depression: psilocybin has been studied as a primary treatment for major depressive disorder, while MDMA has not.

Legally, psilocybin sits in the same narrow place as MDMA in Australia — Schedule 8, authorised prescribers, treatment-resistant depression only — and remains unapproved in the US. If your main problem is depression rather than trauma, psilocybin is the more relevant of the two to watch.

MDMA: the trauma-specific one

MDMA's distinguishing features are specific and worth stating plainly. It is the only one of the four with a Phase 3 trial programme in PTSD, and the only one whose mechanism was designed around the therapy rather than around symptom relief: it reduces the fear response so the memory can be worked with. Its cost is the screening burden — cardiovascular assessment, medication review, and a two-therapist supervised session.

Side by side

The table below reflects the legal position described in this article's sources: MDMA and psilocybin in Australia's Schedule 8 authorised-prescriber scheme, esketamine approved in the US for treatment-resistant depression, and EMDR available as ordinary psychotherapy.

• EMDR — no drug; guideline-recommended for PTSD; widely available; minimal medical screening.
• Ketamine / esketamine — approved in the US for treatment-resistant depression; can be a stand-alone procedure; repeat-dose risks including bladder injury and dependence.
• Psilocybin-assisted therapy — same session structure as MDMA; stronger depression evidence; Schedule 8 in Australia for treatment-resistant depression only.
• MDMA-assisted therapy — Phase 3 data in PTSD; requires cardiovascular screening and medication review; not approved in the US; authorised-prescriber only in Australia.

The comparison nobody publishes

Availability, not efficacy, decides most people's treatment. EMDR is accessible now. Ketamine is accessible with a prescription. MDMA and psilocybin are accessible to a small number of Australians through an ethics-committee-approved prescriber, and to almost nobody else. A treatment you cannot reach has an efficacy of zero for you, however good the trial.

So the honest order of operations is: have you had a guideline-recommended trauma therapy at an adequate dose; are you screened for the things that rule treatments in or out; and can you actually get to the sessions. Only then does the "which drug" question become real.